Publication | Closed Access

Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH

InflammationMetabolic SyndromeCardiovascular DiseaseMedicineAdvanced Glycation EndproductsNonalcoholic SteatohepatitisHyperlipidemiaLipoprotein MetabolismPharmacologyDyslipidemiaSerum Levels